CD 2027

DRUG2 trials

Sponsors

Galderma R&D

Conditions

Plaque-type PsoriasisPsoriasis

Phase 2

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis

CompletedNCT00763503

Galderma R&DPlaque-type Psoriasis

Start: 2008-09-30End: 2009-02-28Updated: 2021-02-18

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

CompletedNCT00763555

Galderma R&DPsoriasis

Start: 2008-09-30End: 2009-03-31Updated: 2022-08-23